# A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Source: https://onco.cc/trials/nct07047118/  
OnCo record `nct07047118` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of JSB462 in prostate cancer, run by Novartis Pharmaceuticals, active and no longer recruiting.

## Summary

A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) is a phase 2 interventional study registered as NCT07047118 by Novartis Pharmaceuticals, with 138 participants enrolled, started 2025-07-03 and due to reach its primary completion in 2027-07-16. Interventions recorded: JSB462 and AAA617.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07047118
- Phase: 2
- Setting: A Phase II, Randomized, Open-label, Multi-center Study of JSB462 (Luxdegalutamide) in Combination With Lutetium (177Lu) Vipivotide Tetraxetan in Adult Male Patients With PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Sponsor: Novartis Pharmaceuticals
- Enrolled: 138

## Sources

- ClinicalTrials.gov NCT07047118: https://clinicaltrials.gov/study/NCT07047118

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- companies: [Advanced Accelerator Applications (Novartis)](https://onco.cc/companies/advanced-accelerator-applications/)

---
JSON: https://onco.cc/api/v1/entities/nct07047118.json